2-(pyridin-3-yloxy)ethyl 4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]-pyridine-5-carboxylate | 1218913-70-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 2-(pyridin-3-yloxy)ethyl 4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]-pyridine-5-carboxylate
• 英文别名: 2-(pyridin-3-yloxy)ethyl 4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate；2-pyridin-3-yloxyethyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate
• CAS: 1218913-70-2
• 化学式: C₁₇H₂₂N₄O₃
• 分子量: 330.387
• InChiKey: MRBONSWYKLRFPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  80.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  、 4-isopropyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine hydrochloride 在 N,N-二异丙基乙胺 、 水 、 sodium hydroxide 作用下， 以 二氯甲烷 、 甲醇 为溶剂， 反应 72.0h， 以1%的产率得到2-(pyridin-3-yloxy)ethyl 4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]-pyridine-5-carboxylate
  参考文献：
  名称：

  [EN] NEW COMPOUNDS I
  [FR] COMPOSÉS INÉDITS I

  摘要：

  本发明涉及式(I)的化合物及其药用可接受的盐、溶剂合物、水合物、几何异构体、互变异构体、光学异构体或N-氧化物，这些化合物是SSAO活性的抑制剂。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物治疗抑制SSAO活性有益的医疗状况，如炎症性疾病和免疫紊乱。

  公开号：

  WO2010031789A1

文献信息

• NEW COMPOUNDS I
  申请人：Savory Edward Daniel

  公开号：US20110207746A1

  公开（公告）日：2011-08-25

  The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.

  本发明涉及公式（I）的化合物及其药学上可接受的盐、溶剂合物、水合物、几何异构体、互变异构体、光学异构体或N-氧化物，它们是SSAO活性的抑制剂。本发明进一步涉及包含这些化合物的制药组合物，以及利用这些化合物治疗抑制SSAO活性有益的医疗状况，例如炎症性疾病和免疫障碍。
• New Compounds I
  申请人：Savory Edward Daniel

  公开号：US20120302583A1

  公开（公告）日：2012-11-29

  The present invention relates to a method for the treatment or prevention of inflammation, an inflammatory disease, an immune or an autoimmune disorder, which comprises administering to a mammal in need of such treatment an effective amount of a compound compound of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity.

  本发明涉及一种治疗或预防炎症、炎症性疾病、免疫或自身免疫性障碍的方法，包括向需要这种治疗的哺乳动物施用式(I)的化合物的有效量，以及它们的药学上可接受的盐、溶剂合物、水合物、几何异构体、互变异构体、光学异构体或N-氧化物，它们是SSAO活性的抑制剂。
• Methods of using 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine compounds
  申请人：Savory Edward

  公开号：US08569338B2

  公开（公告）日：2013-10-29

  The present invention relates to a method for the treatment or prevention of inflammation, an inflammatory disease, an immune or an autoimmune disorder, which comprises administering to a mammal in need of such treatment an effective amount of a compound compound of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity.

  本发明涉及一种治疗或预防炎症、炎症性疾病、免疫或自身免疫性疾病的方法，包括向需要这种治疗的哺乳动物投予化合物公式(I)的有效量，以及它们的药物可接受的盐、溶剂合物、水合物、几何异构体、互变异构体、光学异构体或N-氧化物，这些化合物是SSAO活性的抑制剂。
• 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds
  申请人：Proximagen Ltd

  公开号：US08263616B2

  公开（公告）日：2012-09-11

  The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.

  本发明涉及公式（I）的化合物及其药学上可接受的盐、溶剂合物、水合物、几何异构体、互变异构体、光学异构体或N-氧化物，这些化合物是SSAO活性抑制剂。该发明还涉及包含这些化合物的制药组合物以及这些化合物用于治疗抑制SSAO活性有益的医疗状况，如炎症性疾病和免疫障碍。
• Method of using 4,5,6,7-tetrahydroimidazo[4,5-C]pyridine compounds
  申请人：Proximagen Limited

  公开号：US09035066B2

  公开（公告）日：2015-05-19

  The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.

  本发明涉及公式（I）化合物及其药学上可接受的盐、溶剂合物、水合物、几何异构体、互变异构体、光学异构体或N-氧化物，这些化合物是SSAO活性抑制剂。本发明还涉及包含这些化合物的药物组合物以及利用这些化合物治疗抑制SSAO活性有益的医学状况，例如炎症性疾病和免疫障碍。